Advent Life Sciences
Status
ACTIVE
Global HQ
London, United Kingdom
Countries of investment
- United Kingdom
- United States
- France
- Netherlands
- Belgium
Investment stages
- Seed
- Series A
- Series B
- Series C
- Growth
Industries
- Life Sciences
- Biotechnology
- Pharma
- MedTech
- Medical Devices
- Diagnostics
- Digital Health
About
Advent Life Sciences is a London venture firm spun out of Advent Venture Partners and led by co-founders Shahzad Malik and Raj Parekh, with offices in the UK, France and the US. Its portfolio includes uniQure, Proximie, Cyted Health and F2G, and past exits include Algeta and Avila Therapeutics. In September 2026 the British Business Bank committed £60M to Advent Life Sciences Fund IV and £75M to the Advent Life Sciences Growth Fund.
Advent Life Sciences is a London venture firm spun out of Advent Venture Partners and led by co-founders Shahzad Malik and Raj Parekh, with offices in the UK, France and the US. Its portfolio includes uniQure, Proximie, Cyted Health and F2G, and past exits include Algeta and Avila Therapeutics. In September 2026 the British Business Bank committed £60M to Advent Life Sciences Fund IV and £75M to the Advent Life Sciences Growth Fund.
Investment Thesis
Advent Life Sciences founds and invests in life sciences companies developing new medicines, medical technologies, vaccines and enabling platforms across the UK, Europe and the US, backing first-in-class or best-in-class approaches. It covers the financing path from early-stage company creation through mid and late-stage clinical development, through its flagship fund and a dedicated growth fund.
Manager's Experience
General Partner Shahzad Malik joined Advent in 1999 with a background in clinical medicine and international finance. He has worked with more than 25 portfolio companies, including Algeta, Respivert, Biocartis and Axonics. General Partner Raj Parekh joined in 2005 after more than 20 years in biomedical research, including senior roles at Oxford GlycoSciences, and is chairman of Galapagos. The partnership also includes General Partners Kaasim Mahmood, Dominic Schmidt and Satish Jindal. Its portfolio has produced IPOs including uniQure, Centessa and Aura Biosciences.
Team
Shahzad Malik - General Partner
Raj Parekh - General Partner
Kaasim Mahmood - General Partner
Dominic Schmidt - General Partner
Satish Jindal - General Partner
Fraser Murray - Head of Scientific Evaluation
Don Drakeman - Venture Partner
Portfolio
uniQure
Proximie
Cyted Health
F2G
Beacon Therapeutics
Glycomine
Aura Biosciences
Centessa
Algeta
Biocartis